The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.
Dr. Gopakumar Iyer discussed how to Integrate Novel Therapeutics with trimodal therapy (TMT). Radiation therapy (RT) has ...
4 Further evidence to support MDT comes from the recently published KEYNOTE-564 trial of adjuvant pembrolizumab. In this trial, high-risk RCC patients who underwent a radical or partial nephrectomy ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is ...
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback